Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NCEL Catalyst Timeline
Dated clinical, regulatory and corporate events for NewcelX Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NewcelX Ltd.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How NCEL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mazindol Small MoleculesCompletedNCT02808104 | Attention Deficit Disorder With Hyperactivity | Phase 2 | COMPLETED | 84 | Mar 28, 2017 | ||||||
| Mazindol Small MoleculesCompletedNCT05055024 | Narcolepsy With Cataplexy | Phase 2 | COMPLETED | 52 | Jan 19, 2023 | ||||||
| mazindol Small MoleculesCompletedNCT04923594 | Narcolepsy | Phase 2 | COMPLETED | 67 | Jun 30, 2022 | ||||||
| AstroRx BiologicsCompletedNCT03482050 | ALS (Amyotrophic Lateral Sclerosis) | Phase 1/2 | COMPLETED | 16 | Jun 22, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every NCEL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AstroRx® | multiple sclerosis | Phase 1/2a | 2026-06-15 | enhance myelin debris clearance by microglia; support lymphocyte-mediated immune regulation; accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytesRead More | NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology PlatformRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Samuel OlivierDirector | Buy | 81,818 81,818 held | $2.75 | 04/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NCEL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NCEL for Q3 2026. | ||||
Ownership Trends
NCEL Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How NCEL ranks across every disease it competes in
NCEL News
NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market
NewcelX Ltd. announced a $1.55 million equity financing at $3.29 per share, a 20% premium to its last closing price. The company plans to use the proceeds to advance its lead program, NCEL-101, for type 1 diabetes, including initiating an IND-enabling toxicology study and preparing for a Phase 1/2a clinical trial in 2027. The financing reflects strong investor confidence in NewcelX's strategy.
Read more →NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments
NewcelX Ltd. announced a binding term sheet to divest its Mazindol portfolio to REA Holdings for $500,000 upfront, which includes $30,000 in cash and equity. The deal could yield up to $55 million in milestone payments and tiered royalties. This strategic move allows NewcelX to concentrate on its cell-therapy pipeline while preserving value for CVR holders.
Read more →NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
NewcelX Ltd. will attend the Breakthrough T1D Clinical & Research Congress from October 9-11, 2026, in Philadelphia. The management team aims to discuss their lead program, NCEL-101, which is set for a Phase 1/2a clinical trial. This follows a successful Pre-IND meeting with the FDA, providing clarity on the regulatory pathway for NCEL-101.
Read more →NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
NewcelX Ltd. has announced a $1.4 million equity financing at a 20% premium to its last closing price. The private placement involves selling 347,134 common shares and warrants, with proceeds aimed at advancing its lead program, NCEL-101, for type 1 diabetes. The offering is expected to close around August 14, 2026, pending customary conditions.
Read more →NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
NewcelX Ltd. has been granted a patent in Brazil for its NCEL-101 therapy aimed at treating type 1 diabetes. This patent protects the manufacturing process until November 2036 and follows a successful FDA Type B Pre-IND meeting. The company aims to address the unmet medical needs of the growing type 1 diabetes population in Brazil, which is approximately 500,000 individuals. The patent strengthens NewcelX's global intellectual property portfolio and enhances future partnership opportunities.
Read more →NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
NewcelX has appointed Dr. Camillo Ricordi to its Scientific Advisory Board, enhancing its focus on developing regenerative therapies for type 1 diabetes. This appointment follows a successful FDA Type B Pre-IND meeting for their lead program, NCEL-101, which outlines a clear regulatory path for upcoming clinical trials. Dr. Ricordi's extensive experience in diabetes research is expected to significantly support NewcelX's strategic initiatives.
Read more →NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
NewcelX Ltd. announced a successful Type B Pre-IND meeting with the FDA, receiving positive feedback on its development strategy for NCEL-101, a treatment for type 1 diabetes. The FDA's guidance allows NewcelX to advance toward clinical trials in combination with Eledon Pharmaceuticals' tegoprubart. This milestone is seen as a significant step toward developing a potentially transformative therapy for patients.
Read more →NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
NewcelX has published a peer-reviewed study in Stem Cell Reports highlighting the potential of its AstroRx® therapy for treating chronic demyelinating diseases, including multiple sclerosis. The study demonstrates AstroRx®'s ability to enhance myelin debris clearance and promote oligodendrocyte differentiation. This publication supports NewcelX's ongoing development of scalable stem cell therapies and its lead candidate for type 1 diabetes.
Read more →To the shareholders of NewcelX AG, Kloten, Switzerland Zurich, June 5, 2026 Invitation to the Ordinary Shareholders' Meeting of NewcelX AG, Kloten, Switzerland Dear Shareholder, The board of directors of NewcelX A
NewcelX AG has invited shareholders to its ordinary shareholders' meeting scheduled for June 30, 2026. Key agenda items include the re-election of board members, approval of statutory financial statements for 2025, and examination of the compensation report. The company reported an operating loss for the year 2025, with an accumulated loss amounting to CHF 90,869,091. The board proposes to carry forward this loss to the next financial year, emphasizing the importance of stable governance amidst financial challenges.
Read more →NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
NewCelX Ltd. has submitted a Pre-IND package to the FDA for NCEL-101, aiming to advance to a First-In-Human clinical trial for type 1 diabetes treatment. The therapy combines NCEL-101 with Eledon's tegoprubart, which has shown promise in preserving islet function in prior studies. A Type B pre-IND meeting is scheduled with the FDA to discuss further development plans.
Read more →NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
NewcelX reported its financial results for 2025 and highlighted its collaboration with Eledon Pharmaceuticals on NCEL-101, a potential treatment for Type 1 Diabetes. The company closed a financing round of approximately $3.4 million and appointed a new Chief Medical Officer to enhance its scientific leadership. Looking ahead, NewcelX anticipates accelerated development in 2026, despite facing financial losses and regulatory uncertainties.
Read more →NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
NewcelX Ltd. has updated its corporate presentation to emphasize its flagship Type 1 Diabetes program, NCEL-101, following a strategic collaboration with Eledon Pharmaceuticals. The collaboration aims to integrate NewcelX's stem-cell-derived islet replacement platform with Eledon's immune-modulation therapy. This initiative is expected to support durable graft survival and move towards a potential functional cure for Type 1 Diabetes, which will be presented at the Swiss Biotech Conference.
Read more →NewcelX Announces Pricing of $1.35 Million Equity
NewcelX Ltd. has announced the pricing of a $1.35 million equity financing at a 30% premium over the last closing price. This funding will support the advancement of its lead program, NCEL-101, aimed at treating Type 1 Diabetes. The financing reflects strong confidence from investors and includes participation from existing shareholders. The expected closing date for the offering is around April 15, 2026, conditional on customary closing conditions being met.
Read more →NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals
NewcelX has entered a strategic collaboration with Eledon Pharmaceuticals to enhance its NCEL-101 program for Type 1 Diabetes. This partnership aims to integrate NewcelX's stem-cell-derived therapies with Eledon's investigational anti-CD40L monoclonal antibody, facilitating improved immune modulation. The collaboration is expected to support better durability of cell grafts and streamline regulatory processes. Both companies anticipate that this initiative will help address critical unmet medical needs in diabetes treatment and advance clinical programs more efficiently.
Read more →NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
NewcelX has announced a strategic collaboration with Eledon Pharmaceuticals to advance its NCEL-101 program aimed at treating Type 1 Diabetes. This partnership will integrate stem-cell-derived islets with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart, to enhance graft survival. The collaboration is expected to streamline development and establish a clearer regulatory pathway for NCEL-101.
Read more →NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
NewcelX Ltd. announced a peer-reviewed publication that validates the clinical profile of Mazindol Immediate-Release/Sustained-Release (IR/SR), strengthening its strategic positioning in licensing and acquisition discussions. The article, published in a reputable journal, enhances buyer confidence and supports NewcelX's ongoing negotiations to maximize the asset's value under the Contingent Value Rights (CVR) framework. The company is currently engaged in advanced talks with multiple parties interested in licensing or acquiring Mazindol ER, aiming to convert its scientific strengths into successful financial outcomes. This significant milestone reflects over 20 years of research and development dedicated to the drug's potential applications in various CNS disorders.
Read more →NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
NewcelX Ltd. (NASDAQ: NCEL) has announced an updated corporate presentation ahead of major spring 2026 investor and partnering conferences. The presentation emphasizes the company's strategic commitment to developing cell therapies for Type 1 Diabetes, showcasing recent scientific advancements and clinical objectives. It also highlights the expansion of the Scientific Advisory Board and leadership team, aiming to strengthen its capabilities in cell therapy development. NewcelX plans to engage with potential partners and investors during the upcoming conferences and is eager to share its progress within the biotechnology community.
Read more →NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes
NewcelX has announced positive results from an international study investigating advanced biomaterial approaches for stem cell-derived islet delivery in type 1 diabetes. The research, conducted in collaboration with several universities and organizations, demonstrated that engineered scaffolds incorporating extracellular matrix from a decellularized human pancreas could support islet function effectively. The study's findings align with NewcelX's focus on developing scalable stem cell therapies aimed at treating type 1 diabetes without the need for chronic immune suppression. This progress is supported by additional funding from organizations such as the Australian Foundation for Diabetes Research and Breakthrough T1D.
Read more →NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
NewcelX Ltd. reported positive results from an international study on advanced biomaterial strategies for stem cell-derived islet delivery in Type 1 Diabetes. The research demonstrated that engineered scaffolds with extracellular matrix support islet function effectively. This aligns with NewcelX's goal of developing cell therapies that eliminate the need for immunosuppression.
Read more →NewcelX Appoints Dr. Julien Boisdron, a Swiss in Diabetes Innovation, to Its Scientific Advisory Board
NewcelX Ltd. has appointed Dr. Julien Boisdron, an experienced diabetes expert from a Swiss big pharma, to its Scientific Advisory Board. Dr. Boisdron will provide strategic guidance for NewcelX’s stem-cell-derived islet cell therapy, IsletRx, aimed at treating insulin-dependent Type 1 Diabetes. His background in diabetes care and connected-care innovation is expected to advance the program towards clinical trials and future commercialization. This move strengthens NewcelX's leadership in metabolic and regenerative medicine.
Read more →